<DOC>
	<DOCNO>NCT01077765</DOCNO>
	<brief_summary>Combined antiretroviral therapy ( cART ) associate facial lipoatrophy , potentially stigmatize HIV-positive patient . Eutrophill 2.5 % polyacrylamide hydrogel obtain polymerization acrylamide monomer official half-life 5 year . Preliminary encouraging result use polyacrylamide hydrogel reconstruction facial lipoatrophy HIV-infected patient previously report . The primary objective study evaluate long-term efficacy safety subcutaneous facial injection Eutrophill HIV-infected patient severe facial lipoatrophy assess facial ultrasonography screening , 6 , 12 24 month</brief_summary>
	<brief_title>Polyacrylamide Hydrogel Injection HIV-related Lipoatrophy</brief_title>
	<detailed_description>Combined antiretroviral therapy associate facial lipoatrophy , potentially stigmatize HIV-infected patient . To date , polylactic acid implant ( PLA ) approve correction facial lipoatrophy . The mechanism action increase new collagen synthesis reaction presence implant dermal area . But PLA may associate : subcutaneous micronodules induration mid term relapse lipoatrophy need proceed new PLA injection EUTROPHILL 2.5 % polyacrylamide hydrogel claim half-life 5 years.The gel relatively viscous inject subcutaneously . Following injection , gel encapsulates . The mechanism action increase volume subcutaneous area inert implant The aim multicentric , open-label , single-arm , pilot study evaluate long-term efficacy safety intra-dermal facial injection polyacrylamide hydrogel ( EUTROPHILL ) HIV-infected patient severe facial lipoatrophy . Patients receive 2 6 injection every 4 week , accord aesthetic result . The primary objective study evaluate long-term efficacy subcutaneous facial injection EUTROPHILL HIV-infected patient severe facial lipoatrophy assess facial ultrasonography screening , 6 , 12 24 month The secondary objective study : evaluate clinical efficacy facial photography screening , 6 , 12 24 month ; evaluate Overall Treatment Satisfaction accord patient , close relative physician ; evaluate change quality life ( ABCD questionnaire ) ABCD questionnaire specific questionnaire validate HIV-infected patient suffer lipodystrophy ; evaluate change patient 's anxiety depression ( HADS questionnaire ) ; evaluate safety infiltration technique ;</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>HIVinfected patient 18 year age old Severe facial lipoatrophy . Stable antiretroviral treatment least 3 month prior inclusion CD4 cell count &gt; 100 cells/mm3 Written inform consent History surgical cosmetic intervention facial lipoatrophy Ongoing opportunistic infection Any facial skin disease include Kaposi Sarcoma Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>HIV-associated Lipodystrophy</keyword>
	<keyword>Polyacrylamide hydrogel</keyword>
</DOC>